Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PPAR-gamma agonists and diabetic nephropathy.

Yahua Zhang1, Youfei Guan

  • 1Division of Nephrology and Hypertension, S-3223 MCN, Vanderbilt University Medical Center, Nashville, TN 37232-2372, USA.

Current Diabetes Reports
|December 1, 2005
PubMed
Summary

Diabetic nephropathy, a kidney complication of diabetes, involves albuminuria and declining filtration. Emerging evidence suggests peroxisome proliferator-activated receptor-gamma agonists may effectively treat diabetic renal complications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting REV-ERBα/BNIP3 axis attenuates pulmonary arterial hypertension by repressing mitophagy in mice.

Nature communications·2026
Same author

High-sensitivity on-chip accelerometer based on a coupling-modulation whispering gallery mode microcavity.

Optics express·2026
Same author

K<sub>ir</sub>5.1-modulated potassium flux stimulates an anabolic kidney phenotype.

iScience·2025
Same author

Pregnane X receptor increases urine concentration by upregulating hypothalamic arginine vasopressin expression.

American journal of physiology. Renal physiology·2025
Same author

EP4/ANXA2 axis in pulmonary arterial hypertension: therapeutic implications.

European heart journal·2025
Same author

Knowledge, attitudes, and practices of COPD patients regarding acute exacerbations of COPD.

Frontiers in medicine·2025

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetic nephropathy is a serious complication of diabetes characterized by albuminuria and reduced glomerular filtration rate.
  • It significantly increases the risk of cardiovascular disease.
  • Current treatments for diabetic nephropathy are available but remain suboptimal in managing the condition.

Purpose of the Study:

  • To review emerging evidence on the therapeutic potential of peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonists.
  • To explore the role of PPAR-γ agonists in treating diabetic renal complications.

Main Methods:

  • Literature review of recent studies and evidence.
  • Synthesis of data on the mechanisms and effects of PPAR-γ agonists in diabetic nephropathy models.

Related Experiment Videos

  • Analysis of clinical trial data and observational studies.

    • Main Results:

    • Peroxisome proliferator-activated receptor-gamma agonists show promise in preclinical and clinical studies.
    • These agents may mitigate key pathological features of diabetic nephropathy.
    • Evidence suggests a potential benefit in improving renal outcomes in diabetic patients.

    Conclusions:

    • Peroxisome proliferator-activated receptor-gamma agonists represent a potential new therapeutic strategy for diabetic nephropathy.
    • Further research and clinical trials are warranted to confirm their efficacy and safety.
    • Targeting PPAR-γ may offer a novel approach to managing diabetic renal complications.